Dr. Manji on Treatment for NTRK Fusion+ CRC

Gulam A. Manji, MD, PhD
Published: Tuesday, Sep 17, 2019



Gulam A. Manji, MD, PhD, director, Medical Oncology and Translational Research for The Pancreas Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, discusses treatment for patients with colorectal cancer (CRC) who harbor NTRK fusions.

Patients with NTRK fusion-positive CRC can receive therapy with the FDA-approved TRK inhibitor larotrectinib (Vitrakvi).

Patients who are receiving treatment with this class of agents achieve durable responses, according to Manji, which is very positive for a heavily pretreated population.
SELECTED
LANGUAGE


Gulam A. Manji, MD, PhD, director, Medical Oncology and Translational Research for The Pancreas Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, discusses treatment for patients with colorectal cancer (CRC) who harbor NTRK fusions.

Patients with NTRK fusion-positive CRC can receive therapy with the FDA-approved TRK inhibitor larotrectinib (Vitrakvi).

Patients who are receiving treatment with this class of agents achieve durable responses, according to Manji, which is very positive for a heavily pretreated population.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x